Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Entertainment Now
Spring Wellness
Home & Garden
Home Improvement
Home & Realty
Outdoor Guide
Women
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
Readersâ Choice
Auction
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Replimune Group Inc
(NQ:
REPL
)
18.99
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 31, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
18.99
Bid (Size)
16.58 (1)
Ask (Size)
21.75 (1)
Prev. Close
18.99
Today's Range
18.99 - 18.99
52wk Range
13.84 - 29.52
Shares Outstanding
46,772,263
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Recap: Replimune Group Q4 Earnings
May 18, 2023
Via
Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
April 13, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Performance
YTD
-27.93%
-27.93%
1 Month
+8.51%
+8.51%
3 Month
-14.88%
-14.88%
6 Month
-7.23%
-7.23%
1 Year
+30.70%
+30.70%
More News
Read More
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform
December 12, 2022
Via
Benzinga
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
December 12, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 07, 2022
Via
Benzinga
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
December 07, 2022
Via
Benzinga
Replimune Group: Q2 Earnings Insights
November 03, 2022
Via
Benzinga
Analyst Ratings for Replimune Group
May 24, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Analyst Ratings for Replimune Group
December 07, 2022
Via
Benzinga
Replimune Group: Q3 Earnings Insights
February 03, 2022
Via
Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
December 07, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 07, 2022
Via
Benzinga
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
October 14, 2022
Via
Benzinga
Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday
October 03, 2022
Via
Benzinga
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
May 25, 2022
Via
Benzinga
Replimune Group: Q4 Earnings Insights
May 19, 2022
Via
Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
March 30, 2022
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Via
Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
February 01, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 18, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 20, 2022
Via
Benzinga
10 Biggest Price Target Changes For Monday
August 23, 2021
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Via
Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.